{
    "nct_id": "NCT06692426",
    "official_title": "Phase I Clinical Trial of Cell Based Therapy for Duchenne Muscular Dystrophy",
    "inclusion_criteria": "* Duchenne muscular dystrophy, diagnosed by mutations in the DMD (dystrophin) gene and/or absence of immunohistochemical staining for dystrophin on muscle biopsy\n* Non-ambulatory\n* Intact extensor digitorum brevis (EDB) muscles bilaterally\n* Off investigational therapies for > 30 days\n* Age 18 years of age or older at the time of consent\n* Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to enrollment (28 days for cardiac and pulmonary function):\n* Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) while receiving the study product and for 3 months after stopping tacrolimus therapy.\n* Ability to follow commands sufficiently to perform voluntary aspects of outcome measures throughout the study period\n* Willing to consent to monitoring for 15 years, including an extension period, as required for all interventional studies involving the transplantation of cells that have been genetically modified\n* Voluntary written consent from the subject or parent(s)/guardian(s) and assent from participant prior to the performance of any research related activity.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of HLA antibodies directed toward HLA antigens on MyoPAXon\n* Active treatment with another investigational therapy\n* Known allergy to MyoPAXon components",
    "miscellaneous_criteria": ""
}